At the recent American Association of Clinical Endocrinology (AACE) annual meeting, experts highlighted new approaches to identifying and managing hypercortisolism in patients with type 2 diabetes, ...

a phase 3 trial is ongoing to assess treatment with finerenone (Kerendia, Bayer) in people with type 1 diabetes and CKD. Pantalone said finerenone could be a promising therapeutic option for the ...

The new approval is a key element in Bayer's plans to build Kerendia into a €1 billion-plus ... highest burden of diabetes-related CKD worldwide. "CKD associated with type 2 diabetes has become ...

In addition to GLP-1 medications, a class of medications used in type 2 diabetes called SGLT-2 inhibitors is also being studied for use with type 1 diabetes. GLP-1 drugs can help lower the amount ...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that data from 13 new analyses from across the KERENDIA® (finerenone ... kidney disease (CKD) in type 2 diabetes (T2D), and Real-world ...

associated with type 2 diabetes (T2D) 1 Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for the ...

But the clinical trials of these medications specifically excluded people with type 1 diabetes, who are dependent on the hormone insulin to survive because they can’t make enough of their own ...